jarun011-1
jarun011 / iStockphoto.com
7 September 2017Americas

Bioverativ and Bicycle Therapeutics in $10m haemophilia deal

Biotechnology companies Bioverativ and Bicycle Therapeutics have entered into an agreement to develop and commercialise therapies for haemophilia and sickle cell disease.

The therapeutics will be based on Bicycle Therapeutics’ proprietary bicyclic peptide (Bicycle) product platform.

“Bicycles are a new therapeutic modality that combine attributes of antibodies, small molecules and peptides within one molecule, enabling high selectivity and affinity while simultaneously being able to penetrate and bind to the target(s) of interest within the body,” said the companies.

Announced yesterday, September 6, the deal will see Bicycle receive a $10 million upfront payment, and research and development funding of $4.2 million.

Bicycle is also eligible to receive up to $410 million related to development, regulatory and commercialisation milestones for products planned under the programmes.

Bioverativ will lead preclinical and clinical development, as well as subsequent marketing and commercialisation, while Bicycle Therapeutics will be responsible for leading initial discovery activities.

Tim Harris, executive vice president of research and development at Bioverativ, said: “We are constantly exploring new ways to do innovative science to find new molecules that can advance the care of people living with rare blood disorders.”

Kevin Lee, CEO of Bicycle Therapeutics, added: “Combining Bioverativ’s deep expertise in haematology with our powerful platform offers great promise for the development of novel, targeted therapies for patients.”

Bicycle’s platform is protected through patents and patent applications, assigned from the UK’s Medical Research Council.

In August, LSIPR  reported that the US International Trade Commission (ITC) had instituted a probe into biopharmaceutical company CSL Behring to investigate certain recombinant factor IX products for the treatment of haemophilia B.

Did you enjoy reading this story?  Sign up to our free newsletters and get stories like this sent straight to your inbox.

Sign up for our latest webinar, Biotech patentability issues in Europe.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
20 June 2014   The patent regulatory framework in Mexico needs to evolve if the investment in, and marketing of, promising biotechnology drug products is to succeed, says Hector E. Chagoya.
Americas
30 May 2014   With the Federal Circuit relying on the precedent set by the Prometheus and Myriad decisions, Dolly the sheep has been summarily declared ineligible for patent protection. Nabeela Rasheed sums up the implications.
Americas
27 February 2020   California-headquartered biotech Genentech has agreed to pay $30 million upfront to develop immuno-oncology therapies with UK-based Bicycle Therapeutics.

More on this story

Americas
20 June 2014   The patent regulatory framework in Mexico needs to evolve if the investment in, and marketing of, promising biotechnology drug products is to succeed, says Hector E. Chagoya.
Americas
30 May 2014   With the Federal Circuit relying on the precedent set by the Prometheus and Myriad decisions, Dolly the sheep has been summarily declared ineligible for patent protection. Nabeela Rasheed sums up the implications.
Americas
27 February 2020   California-headquartered biotech Genentech has agreed to pay $30 million upfront to develop immuno-oncology therapies with UK-based Bicycle Therapeutics.

More on this story

Americas
20 June 2014   The patent regulatory framework in Mexico needs to evolve if the investment in, and marketing of, promising biotechnology drug products is to succeed, says Hector E. Chagoya.
Americas
30 May 2014   With the Federal Circuit relying on the precedent set by the Prometheus and Myriad decisions, Dolly the sheep has been summarily declared ineligible for patent protection. Nabeela Rasheed sums up the implications.
Americas
27 February 2020   California-headquartered biotech Genentech has agreed to pay $30 million upfront to develop immuno-oncology therapies with UK-based Bicycle Therapeutics.